NeuroVive Pharmaceutical AB Interim Report January - September 2019
Continued progress in KL1333.Important events July – September
· NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study · NeuroSTAT receives Fast Track designation from the US Food and Drug Administration.
Financial information third quarter (July-September 2019)
· Net revenues: KSEK 0 (0) · Other operating income: KSEK 1,500 (0) · Loss before tax: KSEK -15,297 (-14,982) · Loss per share*: SEK -0.08 (-0.20) · Diluted loss per share**: SEK -0.08 (-0.20)
Financial information first nine months (January-September 2019)
· Net revenues: